LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

LLY

1,019.16

+2.69%↑

JNJ

210.09

+2.68%↑

ABBV

222.92

-0.29%↓

UNH

339.07

+4.39%↑

AZN

90.72

+0.2%↑

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Отворен

0.32

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.32

Максимум

0.32

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
EPS	-0.04
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2.5M 89M
Предишно отваряне	0.32
Предишно затваряне	0.32

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.12.2025 г., 22:02 ч. UTC

Печалби

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10.12.2025 г., 21:46 ч. UTC

Печалби

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10.12.2025 г., 23:52 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 23:43 ч. UTC

Пазарно говорене

Nikkei May Rise After Fed Rate Cut -- Market Talk

10.12.2025 г., 23:36 ч. UTC

Пазарно говорене

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10.12.2025 г., 23:20 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10.12.2025 г., 23:15 ч. UTC

Печалби

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10.12.2025 г., 22:59 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10.12.2025 г., 22:45 ч. UTC

Пазарно говорене

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10.12.2025 г., 22:40 ч. UTC

Печалби

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10.12.2025 г., 22:06 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 22:06 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10.12.2025 г., 22:02 ч. UTC

Печалби

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10.12.2025 г., 22:00 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10.12.2025 г., 21:53 ч. UTC

Печалби

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10.12.2025 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

10.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

10.12.2025 г., 21:45 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10.12.2025 г., 21:33 ч. UTC

Печалби

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10.12.2025 г., 21:32 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10.12.2025 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10.12.2025 г., 21:25 ч. UTC

Печалби

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10.12.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10.12.2025 г., 21:16 ч. UTC

Печалби

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10.12.2025 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10.12.2025 г., 21:15 ч. UTC

Печалби

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10.12.2025 г., 21:14 ч. UTC

Печалби

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10.12.2025 г., 21:14 ч. UTC

Печалби

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.